Improved nerve visualization to reduce unintended intraoperative nerve injury

Illuminare Biotechnologies

Illuminare Biotechnologies is a preclinical stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage. Our proprietary lead candidate, Illuminare-1, is a small molecule with an immediate onset of action and sustained duration of nerve illumination. The IND for Illuminare-1 was approved by the FDA in April 2021 and the product will enter the first-in-human phase 1 clinical trial in at Memorial Sloan Kettering Cancer Center in Q2 2021